Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer

23 Aug 2024

Abstract excerpt

PURPOSE: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning mechanisms remain ill-understood. EXPERIMENTAL DESIGN: We applied targeted cell-free DNA (cfDNA) sequencing to 126 patients with mCRPC from three academic cancer centers and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39177583
DOI: 10.1158/1078-0432.ccr-24-1658

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate CancerPMID 39177583Read ↗

Genomic and epigenomic analysis of plasma cell-free DNA identifies stemness features associated with worse survival in<i>AR</i>-altered lethal prostate cancerSemantic proximity Read ↗

Plasma Cell-Free DNA Chromatin Immunoprecipitation Profiling Depicts Phenotypic and Clinical Heterogeneity in Advanced Prostate Cancer.Semantic proximity Read ↗

Unearthing a Prostate Cancer cfDNA Signature that "Stems" from AR Alterations.Semantic proximity Read ↗

Integrative genomic and epigenomic profiling in plasma and urinary cell-free DNA improves early risk stratification of newly diagnosed prostate cancerSemantic proximity Read ↗

Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancerSemantic proximity Read ↗

The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumorsSemantic proximity Read ↗

Single cell-transcriptomic analysis informs the lncRNA landscape in metastatic castration resistant prostate cancerSemantic proximity Read ↗

Increasing Stemness Drives Prostate Cancer Progression, Plasticity, Therapy Resistance and Poor Patient SurvivalSemantic proximity Read ↗

Integrative dual ctDNA 5mC/5hmC methylomics and clonal reconstruction infer tumor transcription and resistance phenotypes in metastatic prostate cancerSemantic proximity Read ↗

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent subpopulations of cells associated with relapse of prostate cancerSemantic proximity Read ↗

Integrating pharmacogenomics data-driven prediction with bulk and single-cell RNAseq to demonstrate the efficacy of an NAMPT inhibitor against aggressive, taxane-resistant, and stem-like cells in lethal prostate cancerSemantic proximity Read ↗

Noninvasive Detection of Neuroendocrine Prostate Cancer through Targeted Cell-free DNA MethylationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.